These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21491207)

  • 1. Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?
    Hardy J; Norris R; Anderson H; O'Shea A; Charles B
    Support Care Cancer; 2012 Apr; 20(4):767-72. PubMed ID: 21491207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Charles B; Hardy J; Anderson H; Tapuni A; George R; Norris R
    Support Care Cancer; 2014 Feb; 22(2):325-30. PubMed ID: 24077699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?
    George R; Haywood A; Good P; Hennig S; Khan S; Norris R; Hardy J
    Clin Ther; 2017 Sep; 39(9):1840-1848. PubMed ID: 28827023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer.
    Bista SR; Haywood A; Norris R; Good P; Tapuni A; Lobb M; Hardy J
    Clin Ther; 2015 Nov; 37(11):2468-75. PubMed ID: 26404396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
    Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
    Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
    Kokki M; Heikkinen M; Välitalo P; Hautajärvi H; Hokkanen J; Pitkänen H; Sankilampi U; Ranta VP; Kokki H
    Br J Clin Pharmacol; 2017 Apr; 83(4):791-800. PubMed ID: 27780305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
    Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine.
    Moy KV; Ma JD; Morello CM; Atayee RS; Best BM
    J Opioid Manag; 2014; 10(1):47-56. PubMed ID: 24604569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
    Huang L; Edwards SR; Smith MT
    Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
    Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
    PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.
    Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US
    Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
    Mandema JW; Kaiko RF; Oshlack B; Reder RF; Stanski DR
    Br J Clin Pharmacol; 1996 Dec; 42(6):747-56. PubMed ID: 8971431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.
    Cone EJ; DePriest AZ; Heltsley R; Black DL; Mitchell JM; LoDico C; Flegel R
    J Anal Toxicol; 2015 Apr; 39(3):192-202. PubMed ID: 25589778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of oral oxycodone in patients after total gastric resection.
    Szałek E; Karbownik A; Murawa D; Połom K; Tezyk A; Gracz J; Grabowski T; Grześkowiak E; Biczysko-Murawa A; Murawa P
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3126-33. PubMed ID: 25392115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of oxycodone concentrations in oral fluid.
    Moore C; Kelley-Baker T; Lacey J
    J Opioid Manag; 2012; 8(3):161-6. PubMed ID: 22798176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.
    Pantano F; Brauneis S; Forneris A; Pacifici R; Marinelli E; Kyriakou C; Pichini S; Busardò FP
    Clin Chem Lab Med; 2017 Aug; 55(9):1324-1331. PubMed ID: 28080998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.